Panagora Asset Management’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14,818
| Closed | -$128K | – | 1180 |
|
|
2025
Q1 | $128K | Buy |
14,818
+5,231
| +55% | +$45K | ﹤0.01% | 1069 |
|
|
2024
Q4 | $343K | Buy |
9,587
+259
| +3% | +$9.26K | ﹤0.01% | 922 |
|
|
2024
Q3 | $441K | Sell |
9,328
-121
| -1% | -$5.72K | ﹤0.01% | 959 |
|
|
2024
Q2 | $475K | Buy |
9,449
+7
| +0.1% | +$352 | ﹤0.01% | 927 |
|
|
2024
Q1 | $1.06M | Sell |
9,442
-613
| -6% | -$68.7K | 0.01% | 778 |
|
|
2023
Q4 | $583K | Sell |
10,055
-17
| -0.2% | -$986 | ﹤0.01% | 955 |
|
|
2023
Q3 | $320K | Sell |
10,072
-788
| -7% | -$25K | ﹤0.01% | 1063 |
|
|
2023
Q2 | $893K | Buy |
10,860
+2,212
| +26% | +$182K | 0.01% | 821 |
|
|
2023
Q1 | $889K | Buy |
8,648
+1,009
| +13% | +$104K | 0.01% | 882 |
|
|
2022
Q4 | $1.12M | Buy |
7,639
+168
| +2% | +$24.6K | 0.01% | 845 |
|
|
2022
Q3 | $1.26M | Buy |
+7,471
| New | +$1.26M | 0.01% | 765 |
|
|
2021
Q3 | – | Sell |
-9
| Closed | -$3K | – | 2120 |
|
|
2021
Q2 | $3K | Sell |
9
-710
| -99% | -$237K | ﹤0.01% | 2578 |
|
|
2021
Q1 | $291K | Sell |
719
-47
| -6% | -$19K | ﹤0.01% | 1577 |
|
|
2020
Q4 | $508K | Buy |
766
+47
| +7% | +$31.2K | ﹤0.01% | 1223 |
|
|
2020
Q3 | $335K | Sell |
719
-3,727
| -84% | -$1.74M | ﹤0.01% | 1308 |
|
|
2020
Q2 | $2.6M | Sell |
4,446
-2,124
| -32% | -$1.24M | 0.02% | 579 |
|
|
2020
Q1 | $957K | Buy |
6,570
+1,604
| +32% | +$234K | 0.01% | 862 |
|
|
2019
Q4 | $711K | Sell |
4,966
-6,556
| -57% | -$939K | ﹤0.01% | 1178 |
|
|
2019
Q3 | $455K | Buy |
11,522
+7,599
| +194% | +$300K | ﹤0.01% | 1320 |
|
|
2019
Q2 | $397K | Buy |
+3,923
| New | +$397K | ﹤0.01% | 1510 |
|